Abstract
Erythropoietin (EPO), recognized early as a tissue protective agent, can trigger antiinflammatory and anti-apoptotic processes to delimit injury and promote repair by binding tissueprotective receptor (TPR). However, only at a high dosage can EPO exert tissue protective effect, which may elicit severe side-effects at the meantime. Helix B surface peptide (HBSP), a 11-amnio acid sequence derived from the non-erythropoietic helix B of EPO, not only shows higher affinity to TPR but also plays a more specific and powerful role in tissue protection without erythropoietic side-effects. While it has obvious merits, the 2-min plasma half-life of HBSP restricts its application in vivo. Therefore, based on the amino acid sequence of HBSP, we originally designed and synthesized thioethercyclized helix B peptide (CHBP) for an increased resistance to proteolytic degradation as well as an improved tissue protective potency, implying a brighter prospective for translational application. In this review, we will mainly discuss the development from EPO to CHBP, the merits and limitation of CHBP and the probable mechanism mediating tissue protection.
Keywords: Erythropoietin, HBSP, CHBP, ischemia-reperfusion injury, tissue protection, derivatives.
Current Protein & Peptide Science
Title:From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger
Volume: 18 Issue: 12
Author(s): Chao Zhang, Cheng Yang and Tongyu Zhu*
Affiliation:
- Department of Urology, Zhongshan Hospital, Fudan University; Shanghai Key Laboratory of Organ Transplantation; 180 Fenglin Road, Shanghai, 200032,China
Keywords: Erythropoietin, HBSP, CHBP, ischemia-reperfusion injury, tissue protection, derivatives.
Abstract: Erythropoietin (EPO), recognized early as a tissue protective agent, can trigger antiinflammatory and anti-apoptotic processes to delimit injury and promote repair by binding tissueprotective receptor (TPR). However, only at a high dosage can EPO exert tissue protective effect, which may elicit severe side-effects at the meantime. Helix B surface peptide (HBSP), a 11-amnio acid sequence derived from the non-erythropoietic helix B of EPO, not only shows higher affinity to TPR but also plays a more specific and powerful role in tissue protection without erythropoietic side-effects. While it has obvious merits, the 2-min plasma half-life of HBSP restricts its application in vivo. Therefore, based on the amino acid sequence of HBSP, we originally designed and synthesized thioethercyclized helix B peptide (CHBP) for an increased resistance to proteolytic degradation as well as an improved tissue protective potency, implying a brighter prospective for translational application. In this review, we will mainly discuss the development from EPO to CHBP, the merits and limitation of CHBP and the probable mechanism mediating tissue protection.
Export Options
About this article
Cite this article as:
Zhang Chao, Yang Cheng and Zhu Tongyu*, From Erythropoietin to Its Peptide Derivatives: Smaller but Stronger, Current Protein & Peptide Science 2017; 18 (12) . https://dx.doi.org/10.2174/1389203717666160909130006
DOI https://dx.doi.org/10.2174/1389203717666160909130006 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Platelet Function and Signaling by Flavonoids
Mini-Reviews in Medicinal Chemistry Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Cardioprotection Techniques: Preconditioning, Postconditioning and Remote Con-ditioning (Basic Science)
Current Pharmaceutical Design Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery